---

Assessment of efficacy and tolerability of olanzapine, risperidone, amisulpride and quetiapine at 4weeks in newly diagnosed patients of schizophrenia at M.Y. Hospital, Indore

---

Original Article

Author Details : Gopal Gudsurkar, Pali Rastogi, Pooja Solanki, Shubham Atal

Volume : 4, Issue : 3, Year : 2017

Article Page : 120-124

Suggest article by email

Get Permission

---

Abstract

Objectives: Schizophrenia is a psychotic disorder characterized by hallucinations and delusions. Second generation antipsychotics are frequently used to treat the schizophrenia. As there are no clear-cut Indian guidelines for starting a particular drug for newly diagnosed cases of schizophrenia we decided to find out efficacy and tolerability of olanzapine, risperidone, quetiapine and amisulpride at 4 weeks after the initiation of treatment.
Materials and Method: Newly diagnosed cases of schizophrenia of either sex between age group 18 to 65 were recruited;30 cases in each group[N-120, n-30]. Patients were prescribed either of the study drugs in oral tablet form. Efficacy was assessed by comparing baseline [day 0] and week 4scores of PANSS, CGI and GAF score and tolerability was assessed by UKU PERT scale at 4 week.
Results: Olanzapine and risperidone statistically significantly reduced total PANSS score than amisulpride and quetiapine (p<0.05).Olanzapine, risperidone and quetiapine reduced PANSS positive sub score significantly than amisulpride (p<0.05).Quetiapine reduced the PANSS negative sub score significantly than amisulpride (p<0.05).Olanzapine and risperidone were slightly better than amisulpride and quetiapine in reducing CGI-S score and improving GAF score. All drugs were equally tolerable at the end of 4 weeks.

Keywords: Schizophrenia, PANSS, CGI, GAF

How to cite : Gudsurkar G, Rastogi P, Solanki P, Atal S, Assessment of efficacy and tolerability of olanzapine, risperidone, amisulpride and quetiapine at 4weeks in newly diagnosed patients of schizophrenia at M.Y. Hospital, Indore. Indian J Pharm Pharmacol 2017;4(3):120-124

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.